160 related articles for article (PubMed ID: 37116853)
1. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
3. 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.
Han M; Shen J; Wang L; Wang Y; Zhai X; Li Y; Liu M; Li Z; Zuo D; Wu Y
Chem Biol Interact; 2018 Mar; 284():24-31. PubMed ID: 29458018
[TBL] [Abstract][Full Text] [Related]
4. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
[TBL] [Abstract][Full Text] [Related]
5. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
Wang L; Xu X; Liu T; Wang J; Shen J; Guo M; Wu Y; Zhai X; Zuo D
J Pharm Pharmacol; 2020 Oct; 72(10):1370-1382. PubMed ID: 32596809
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
[TBL] [Abstract][Full Text] [Related]
7. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
Yang L; Li G; Zhao L; Pan F; Qiang J; Han S
Tumour Biol; 2014 Oct; 35(10):9759-67. PubMed ID: 24972969
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
Li Y; Ye X; Liu J; Zha J; Pei L
Neoplasia; 2011 Jan; 13(1):1-11. PubMed ID: 21245935
[TBL] [Abstract][Full Text] [Related]
9. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract][Full Text] [Related]
11. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
12. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
13. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Du P; Hu T; An Z; Li P; Liu L
Cancer Sci; 2020 Jun; 111(6):1887-1898. PubMed ID: 32227409
[TBL] [Abstract][Full Text] [Related]
15. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
17. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells.
Chang X; Wang J; Bian J; Liu Z; Guo M; Li Z; Wu Y; Zhai X; Zuo D
Toxicol Appl Pharmacol; 2022 Sep; 450():116156. PubMed ID: 35803438
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract][Full Text] [Related]
19. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
20. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]